Mirrors of Medicine· @mirrorsmed · X·· 3 天前评分70
正文 · 机器翻译
期待 #ESMO26 上的这项研究 👀
FOURLIGHT-1：一款 CDK4 选择性抑制剂，在 CDK4/6i 治疗后进展的情况下优于标准治疗方案（PFS HR 0.60），且仅 4% 的患者因毒性而停药。这会不会是我们后 CDK4/6i 序贯治疗路径中的下一步？#BreastCancer
敬请关注 @mirrorsmedicine 对 ESMO 的报道！
421 浏览 · 2 赞 · 2 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.orgOncoAlert 4Sight Abstracts to be Presented at #ESMO26 Efficacy and Safety of Atirmociclib + Fulvestrant in Patients With HR+/HER2– Advanced/Metastatic Breast Cancer Who Progressed on Prior CDK4/6 Inhibitor in a Randomized Phase 2 Study (FOURLIGHT-1) @antgiorda 🔬 Randomized phase 2 (n=263): atirmociclib + fulvestrant vs investigator’s choice (fulvestrant or everolimus + exemestane) in HR+/HER2– mBC after prior CDK4/6i. Primary: investigator-assessed PFS. ➡️ Median PFS 9.4 vs 6.6 mo; HR 0.60 (0.440–0.825); 1-sided p=0.0007 ➡️ ORR in patients with measurable disease: 19.3% vs 11.3%; CBR: 61.9% vs 46.0% ➡️ Atirmociclib discontinuation due to TRAEs: 4.0%; most common TRAE neutropenia (46.4%) ✅ First next-generation CDKi to show significant and clinically meaningful PFS improvement after prior CDK4/6i, with a manageable safety profile. #BreastCancer 🎙️ Antonio Giordano (4Sight Made from Abstracts publicly available at the ESMO website) @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista @guiandri76在 X 查看被引用的帖子
来源：Mirrors of Medicine · x.com